نتایج جستجو برای: fgfr3

تعداد نتایج: 1106  

Journal: :Cancer research 2001
B W van Rhijn I Lurkin F Radvanyi W J Kirkels T H van der Kwast E C Zwarthoff

We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer. A FGFR3 mutation was found in 34 of 53 pTaG1-2 bladder cancers, whereas none of the 19 higher-staged tumors had a mutation (P < 0.0001). In 57 patients with superficial disease followed prospectively by cystoscopy for 12 months, 14 of 23 patients in the w...

2017
Kirsi J Granberg Matti Annala Birgitta Lehtinen Juha Kesseli Joonas Haapasalo Pekka Ruusuvuori Olli Yli-Harja Tapio Visakorpi Hannu Haapasalo Matti Nykter Wei Zhang

Background Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treatment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have responded well to FGFR inhibition. As high FGFR3 expression has ...

2016
Siru Zhou Yangli Xie Wei Li Junlan Huang Zuqiang Wang Junzhou Tang Wei Xu Xianding Sun Qiaoyan Tan Shuo Huang Fengtao Luo Meng Xu Jun Wang Tingting Wu Liang chen Hangang Chen Nan Su Xiaolan Du Yue Shen Lin Chen

Osteoarthritis (OA) in the temporomandibular joint (TMJ) is a common degenerative disease in adult, which is characterized by progressive destruction of the articular cartilage. To investigate the role of FGFR3 in the homeostasis of TMJ cartilage during adult stage, we generated Fgfr3(f/f); Col2a1-CreER(T2) (Fgfr3 cKO) mice, in which Fgfr3 was deleted in chondrocytes at 2 months of age. OA-like...

2014
Elizabeth A Guancial Lillian Werner Joaquim Bellmunt Aristotle Bamias Toni K Choueiri Robert Ross Fabio A Schutz Rachel S Park Robert J O'Brien Michelle S Hirsch Justine A Barletta David M Berman Rosina Lis Massimo Loda Edward C Stack Levi A Garraway Markus Riester Franziska Michor Philip W Kantoff Jonathan E Rosenberg

While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embe...

2016
Yongjun Yin Xiaodi Ren Craig Smith Qianxu Guo Maria Malabunga Ilhem Guernah Yiwei Zhang Juqun Shen Haijun Sun Nabil Chehab Nick Loizos Dale L. Ludwig David M. Ornitz

Activating mutations in fibroblast growth factor receptor 3 (FGFR3) have been identified in multiple types of human cancer and in congenital birth defects. In human lung cancer, fibroblast growth factor 9 (FGF9), a high-affinity ligand for FGFR3, is overexpressed in 10% of primary resected non-small cell lung cancer (NSCLC) specimens. Furthermore, in a mouse model where FGF9 can be induced in l...

Journal: :Human molecular genetics 2012
Emilie Mugniery Romain Dacquin Caroline Marty Catherine Benoist-Lasselin Marie-Christine de Vernejoul Pierre Jurdic Arnold Munnich Valérie Geoffroy Laurence Legeai-Mallet

The fibroblast growth factor receptor 3 (FGFR3) plays a critical role in the regulation of endochondral ossification. Fgfr3 gain-of-function mutations cause achondroplasia, the most common form of dwarfism, and a spectrum of chondrodysplasias. Despite a significant number of studies on the role of FGFR3 in cartilage, to date, none has investigated the influence of Fgfr3-mediated effects of the ...

2016
Koos Koole Pauline M. W. van Kempen Justin E. Swartz Ton Peeters Paul J. van Diest Ron Koole Robert J. J. van Es Stefan M. Willems

Fibroblast growth factor receptor 3 (FGFR3) is a member of the fibroblast growth factor receptor tyrosine kinase family. It has been identified as a promising therapeutic target in multiple types of cancer. We have investigated FGFR3 protein expression and FGFR3 gene copy-numbers in a single well-documented cohort of oral and oropharyngeal squamous cell carcinoma. Tissue microarray sets contain...

2017
Shuyang Sun Yilong Wang Rong Zhou Zicheng Deng Yong Han Xiao Han Wenjie Tao Zi Yang Chaoji Shi Duo Hong Jiang Li Donglu Shi Zhiyuan Zhang

In precision cancer nanomedicine, the key is to identify the oncogenes that are responsible for tumorigenesis, based on which these genetic drivers can be each specifically regulated by a nanovector-directed, oncogene-targeted microRNA (miRNA) for tumor suppression. Fibroblast Growth Factor Receptor 3 (FGFR3) is such an oncogene. The molecular tumor-subtype harboring FGFR3 genomic alteration ha...

Journal: :Cancer research 2008
April N Meyer Christopher W McAndrew Daniel J Donoghue

Activating mutations within fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase, are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes, Thanatophoric Dysplasia (TD) type I and II. Several of these same FGFR3 mutations have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma, and c...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2009
Jonathan R St-Germain Paul Taylor Jiefei Tong Lily L Jin Ana Nikolic Ian I Stewart Robert M Ewing Moyez Dharsee Zhihua Li Suzanne Trudel Michael F Moran

Signaling by growth factor receptor tyrosine kinases is manifest through networks of proteins that are substrates and/or bind to the activated receptors. FGF receptor-3 (FGFR3) is a drug target in a subset of human multiple myelomas (MM) and is mutationally activated in some cervical and colon and many bladder cancers and in certain skeletal dysplasias. To define the FGFR3 network in multiple m...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید